Thus, in spite of the encouraging data of IL-15 immunotherapy in murine models, together with its low toxicity in mice and primates that has led to the design of clinical trials in AML patients, the use of IL-15 in vivo as monotherapy or combined therapy in AML patients requires special caution. Here, IL15 is linked to acute myeloid leukemia.